Phibro Animal Health Corporation (NASDAQ:PAHC) Given Average Recommendation of “Hold” by Analysts

Phibro Animal Health Corporation (NASDAQ:PAHC) has earned an average recommendation of “Hold” from the eight analysts that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $31.40.

Several brokerages recently commented on PAHC. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research report on Monday. JPMorgan Chase & Co. upped their target price on shares of Phibro Animal Health from $45.00 to $50.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. Finally, Zacks Research raised shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th.

Phibro Animal Health Trading Down 0.4%

Shares of Phibro Animal Health stock opened at $37.36 on Friday. The firm has a market capitalization of $1.51 billion, a PE ratio of 22.51, a P/E/G ratio of 1.06 and a beta of 0.79. Phibro Animal Health has a twelve month low of $16.16 and a twelve month high of $46.42. The firm’s 50-day moving average price is $41.17 and its 200 day moving average price is $35.89. The company has a current ratio of 3.09, a quick ratio of 1.35 and a debt-to-equity ratio of 2.32.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.73 EPS for the quarter, topping the consensus estimate of $0.58 by $0.15. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.The company had revenue of $363.89 million during the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, sell-side analysts predict that Phibro Animal Health will post 1.95 EPS for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were paid a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend was Wednesday, November 26th. Phibro Animal Health’s dividend payout ratio (DPR) is 28.92%.

Insider Activity

In related news, CEO Jack Bendheim sold 5,752 shares of the stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $40.93, for a total value of $235,429.36. Following the completion of the sale, the chief executive officer owned 39,200 shares of the company’s stock, valued at approximately $1,604,456. This trade represents a 12.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 146,554 shares of company stock valued at $6,338,444 in the last ninety days. 50.13% of the stock is owned by corporate insiders.

Institutional Trading of Phibro Animal Health

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its holdings in shares of Phibro Animal Health by 1,730.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after acquiring an additional 225,110 shares during the period. Tudor Investment Corp ET AL grew its holdings in shares of Phibro Animal Health by 3.4% in the third quarter. Tudor Investment Corp ET AL now owns 10,184 shares of the company’s stock valued at $412,000 after purchasing an additional 338 shares during the period. Danske Bank A S acquired a new stake in Phibro Animal Health during the third quarter worth about $955,000. Advisory Services Network LLC purchased a new position in Phibro Animal Health during the third quarter worth about $96,000. Finally, Dark Forest Capital Management LP acquired a new position in Phibro Animal Health in the 3rd quarter valued at about $2,751,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.